Bright Minds Biosciences develops highly selective 5-HT2A and 5-HT2C agonists to treat mental health disorders, utilizing a proprietary chemistry platform that minimizes 5-HT2B activity. Their therapeutics aim to address treatment-resistant depression and other central nervous system disorders by promoting neuroplasticity and providing fast-onset effects.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for mental health disorders and neurological conditions like epilepsy and treatment-resistant depression often lack efficacy or have undesirable side effects due to non-selective targeting within the central nervous system. Traditional therapeutics may not effectively promote neuroplasticity or provide rapid relief for patients suffering from these debilitating conditions.
Solution
Bright Minds Biosciences is developing a new generation of highly selective 5-HT2A and 5-HT2C agonists designed to address the limitations of existing treatments for neuropsychiatric disorders. Utilizing a proprietary chemistry platform, Bright Minds is creating compounds that minimize 5-HT2B activity to improve safety profiles and optimize therapeutic effects. Their drug candidates are designed to promote neuroplasticity and offer fast-onset action, with the goal of providing more effective relief for conditions such as treatment-resistant depression and rare epilepsies. The company's pipeline includes both hallucinogenic and non-hallucinogenic psychoplastogens, as well as compounds targeting obesity and feeding behavior.
Target Audience
The primary target audience includes individuals suffering from treatment-resistant depression, epilepsy, and other central nervous system disorders, as well as the physicians and healthcare providers who treat them.
Features
- Highly selective 5-HT2A and 5-HT2C agonists with minimized 5-HT2B activity
- Biased agonism with minimal arrestin recruitment for improved safety and efficacy
- "Fast-On-Fast-Off" compounds with high Cmax and short plasma half-life for rapid onset of action
- Non-hallucinogenic psychoplastogens that promote neuroplasticity
- Compounds suitable for chronic dosing
- Potential for pro-cognitive effects
- Focus on treatment-resistant depression, rare epilepsies, obesity, and other CNS disorders
- Application of computational chemistry for rapid identification of promising compounds